Dosing & Uses
Dosage Forms & Strengths
naphazoline/pheniramine
ophthalmic solution
- 0.025%/0.3%
- 0.027%/0.3%
Allergic Conjunctivitis
Instill 1-2 drops in affected eye(s) up to 4 times daily
Other Information
Remove contact lenses before using
Store at room temp; protect from light and excessive heat; use before expiration date
Dosage Forms & Strengths
naphazoline/pheniramine
ophthalmic solution
- 0.025%/0.3%
- 0.027%/0.3%
Allergic Conjunctivitis
<6 years: Not established
6 years or older: 1-2 drops in affected eye(s) up to 4 times daily
Other Information
Remove contact lenses before using
Store at room temp; protect from light and excessive heat; use before expiration date
Adverse Effects
Frequency Not Defined
Stinging/tingling sensation upon instillation
Mydriasis
Ocular erythema
Warnings
Contraindications
Hypersensitivity
Cautions
For external use only
Do not use if solution becomes cloudy
Ask healthcare professional if diagnosed with narrow-angle glaucoma, hypertension, heart disease, or benign prostatic hypertrophy
Treatment may cause pupils to become enlarged temporarily, causing light sensitivity
Overuse may cause more eye redness
Remove contact lenses before using; wait 15 minutes after dosing to apply them back on
Do not touch tip of container to any surface to avoid contamination
Replace cap after each use
Ask healthcare practitioner if feel eye pain, changes in vision occur, or redness or irritation of the eyes gets worse or lasts more than 72 hours
Keep out of reach of children; if swallowed, get medical help or contact a Poison Control Center right away; accidental swallowing by infants and children may lead to coma and marked reduction in body temperature
Pregnancy & Lactation
Pregnancy
There are no or limited amount of data from use of topical ophthalmic naphazoline or pheniramine in pregnant women; animal studies are insufficient with respect to reproductive toxicity
Lactation
Unknown whether topical naphazoline/metabolites are excreted in human milk; however, a risk to suckling child cannot be excluded
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Absorption: Negligible systemic absorption
Mechanism of Action
Naphazoline: alpha-adrenergic agonist (decongestant)
Pheniramine: H1 blocker (antihistamine)
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
Opcon-A ophthalmic (eye) - | 0.02675-0.315 % drops | ![]() | |
Naphcon-A ophthalmic (eye) - | 0.025-0.3 % drops | ![]() | |
Naphcon-A ophthalmic (eye) - | 0.025-0.3 % drops | ![]() | |
Eye Allergy Relief (naphazoline-pheniramine) - | 0.025-0.3 % drops | ![]() |
Copyright © 2010 First DataBank, Inc.